Evidence map›Paper›PMID 35117186›Full record

ArticleTranslational cancer research2020

N

Gao Li, Yue Zhang, Xiaowei Du, Wanjun Li, Yanming Zhang, Tao Han, Zhendong Zheng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. RNA m6A methylation regulators in liver cancer.Cancer cell international · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gao Li *Department of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Yue Zhang *Department of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Xiaowei Du *Department of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Wanjun Li *Department of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Yanming ZhangDepartment of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Tao HanDepartment of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
Zhendong ZhengDepartment of Oncology, Cancer Center, General Hospital of Northern Theater Command, Shenyang 110840, China.
General Hospital of Shenyang Military Region · CNJinzhou Medical University · CNShenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN

methodsA total of 13 m

resultsEleven of the 13 molecules were higher in the liver cancer tissues than the adjacent tissues (P<0.05), and most were significantly positively related. Two subgroup models were constructed. Subgroup 2 patients had higher levels of alpha-fetoprotein (AFP), while grade and the three-year survival were lower than subgroup 1 (49%

conclusionsThe abnormal expression of m

Indexed as

epigeneticshepatocellular carcinoma (HCC)m6A RNA methylationprognostic signature

Identifiers

PMID35117186
PMCPMC8797315
OpenAlexW2996964534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.